BRPI0717774A2 - Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina - Google Patents

Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina

Info

Publication number
BRPI0717774A2
BRPI0717774A2 BRPI0717774-7A2A BRPI0717774A BRPI0717774A2 BR PI0717774 A2 BRPI0717774 A2 BR PI0717774A2 BR PI0717774 A BRPI0717774 A BR PI0717774A BR PI0717774 A2 BRPI0717774 A2 BR PI0717774A2
Authority
BR
Brazil
Prior art keywords
stansoporfine
hyperbilyrubinemia
newborn
dosage
treatment
Prior art date
Application number
BRPI0717774-7A2A
Other languages
English (en)
Inventor
Benjamin Levinson
Simon Tulloch
Original Assignee
Infacare Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infacare Pharmaceutical Corp filed Critical Infacare Pharmaceutical Corp
Publication of BRPI0717774A2 publication Critical patent/BRPI0717774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0717774-7A2A 2006-10-04 2007-10-04 Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina BRPI0717774A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84950906P 2006-10-04 2006-10-04
PCT/US2007/021486 WO2008045378A2 (en) 2006-10-04 2007-10-04 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin

Publications (1)

Publication Number Publication Date
BRPI0717774A2 true BRPI0717774A2 (pt) 2014-04-29

Family

ID=39036883

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717774-7A2A BRPI0717774A2 (pt) 2006-10-04 2007-10-04 Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina

Country Status (13)

Country Link
US (1) US20080113955A1 (pt)
EP (1) EP2076273A2 (pt)
JP (1) JP2010505854A (pt)
KR (1) KR20090079916A (pt)
CN (1) CN101631554A (pt)
AU (1) AU2007307112A1 (pt)
BR (1) BRPI0717774A2 (pt)
CA (1) CA2664934A1 (pt)
EA (1) EA200970345A1 (pt)
IL (1) IL197839A0 (pt)
MX (1) MX2009003532A (pt)
NO (1) NO20091580L (pt)
WO (1) WO2008045378A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture
US7960371B2 (en) 2006-10-04 2011-06-14 Infacare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
US20090293326A1 (en) * 2008-05-29 2009-12-03 Bedford Nieves-Cruz Hyperbilirubinemia management calendar
RU2414879C2 (ru) * 2009-01-11 2011-03-27 Николай Федосеевич Давыдкин Способ лечения гипербилирубинемии новорожденных
RU2389499C1 (ru) * 2009-02-10 2010-05-20 Иван Ильич Таранов Способ лечения больных с гипербилирубинемией
PL2691398T3 (pl) 2011-03-30 2017-07-31 Infacare Pharmaceutical Corporation Sposoby syntezy mezoporfiryn metali
AU2012345646A1 (en) * 2011-12-01 2014-06-26 Infacare Pharmaceutical Corporation Methods for treating hyperbilirubinemia with stannsoporfin
EP3455894A4 (en) * 2016-05-12 2020-03-11 Mallinckrodt Hospital Products IP Limited METHODS OF TREATING HYPER-BILIRUBINEMIA WITH STANNSOPORFIN AND PHOTOTHERAPY
WO2021126855A1 (en) * 2019-12-16 2021-06-24 Mallinckrodt Hospital Products IP Unlimited Company Methods for treating progressive hyperbilirubinemia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US4900871A (en) * 1987-01-02 1990-02-13 Sun Refining And Marketing Company Hydrocarbon oxidations catalyzed by iron coordination complexes containing a halogenated ligand
US5990363A (en) * 1987-01-02 1999-11-23 Sun Company, Inc. Method for oxidizing alkanes using novel porphyrins synthesized from dipyrromethanes and aldehydes
US5062775A (en) * 1989-09-29 1991-11-05 Rocky Mountain Research, Inc. Roller pump in an extra corporeal support system
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5817830A (en) * 1992-08-14 1998-10-06 Trustees Of The University Of Pennsylvania Pyrrolic compounds
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
WO1994028906A1 (en) * 1993-06-14 1994-12-22 The Rockefeller University Treatment of neonatal hyperbilirubin with metalloporphyrin
CA2130853A1 (en) * 1994-08-25 1996-02-26 Svetlana Kudrevich Process for the syntheses of monosulphonated phthalocyanines, naphthobenzoporphyrazines and porphyrins via a modified meerwein reaction
US5912341A (en) * 1995-03-14 1999-06-15 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
WO1997005152A1 (en) * 1995-08-02 1997-02-13 Warner-Lambert Company Amino acid complexes of cobalt (iii) mesoporphyrin ix and cobalt (iii) protoporphyrin ix
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US6004530A (en) * 1996-06-04 1999-12-21 Roche Diagnostics Gmbh Use of metallo-porphyrin conjugates for the detection of biological substances
GB9616353D0 (en) * 1996-08-03 1996-09-11 Secr Defence Metallo-porphyrins
US6124452A (en) * 1997-12-19 2000-09-26 University Of Nebraska-Lincoln Octafluoro-meso-tetraarylporphyrins and methods for making these compounds
DE19706490C1 (de) * 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6194566B1 (en) * 1997-12-02 2001-02-27 Schering Aktiengesellschaft Process for the production of metalloporphyrin-metal complex conjugates
JP3673888B2 (ja) * 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US5973141A (en) * 1998-11-27 1999-10-26 Miravant Pharmaceuticals, Inc. Method for the demethoxycarbonylation of porphyrinic compounds such as pheophorbides
US6462192B2 (en) * 2001-01-23 2002-10-08 Miravant Pharmaceuticals, Inc. Processes for large scale production of tetrapyrroles
CA2448570A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
US7375216B2 (en) * 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
AU2003237349B2 (en) * 2002-06-04 2010-06-03 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin halide compounds
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture

Also Published As

Publication number Publication date
EP2076273A2 (en) 2009-07-08
JP2010505854A (ja) 2010-02-25
EA200970345A1 (ru) 2009-10-30
WO2008045378A3 (en) 2008-06-05
CA2664934A1 (en) 2008-04-17
AU2007307112A1 (en) 2008-04-17
NO20091580L (no) 2009-05-04
WO2008045378A2 (en) 2008-04-17
CN101631554A (zh) 2010-01-20
IL197839A0 (en) 2009-12-24
KR20090079916A (ko) 2009-07-22
MX2009003532A (es) 2009-06-26
US20080113955A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
BRPI0717774A2 (pt) Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina
HRP20190306T1 (hr) Niže jačine doze formulacija imikvimoda i kratki režimi doziranja kod liječenja aktinične keratoze
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
CR10769A (es) Improvements in and relating to drive mechanisms suitable for use in drug delicery devices
BRPI0906735A2 (pt) Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4
ITMI20060184U1 (it) Deambulatore magico
IL209738B (en) Combination of cannabidiol and tetrahydrocannabidinol (thc) for use in treating glioblastoma
PL1993559T3 (pl) Leczenie niedoboru i deficytu witaminy d z zastosowaniem 25-hydroksywitaminy d2 i 25-hydroksywitaminy d3
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
EP1983965A4 (en) PHOTODYNAMIC COSMETIC PROCEDURE AND HEALING PROCESS
DK3072504T3 (da) Orale transmukosale doseringsformer i små volumener
ZA200808699B (en) Light emitting device for use in therapeutic and/or cosmetic treatment
EP2087871A4 (en) VOIDABLE ARTICLE
EP2067458A4 (en) VOIDABLE ARTICLE
EP2034073A4 (en) VOIDABLE ARTICLE
ATE554075T1 (de) Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
EP2079489A4 (en) ABSORBENT ARTICLE WITH ABSORPTION STRUCTURE
DK2035369T3 (da) Terapeutiske
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
DK2297106T3 (da) Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
DK1999403T3 (da) Multikoblingssystem og fremgangsmåde relateret dertil
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
EP2096927A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING WITH CAPSIANOSIDE COMPOUNDS
EP2046368A4 (en) ANTI-COCAINE COMPOSITIONS AND TREATMENT

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.